We are live on ! Find out more
CALA

Calithera Biosciences

Delisted

CALA was delisted on the 1st of February, 2023.

92 hedge funds and large institutions have $134M invested in Calithera Biosciences in 2019 Q2 according to their latest regulatory filings, with 27 funds opening new positions, 36 increasing their positions, 16 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

2,660% more capital inflows, than outflows

Capital inflows: $74.1M | Capital outflows: $2.69M

575% more first-time investments, than exits

New positions opened: 27 | Existing positions closed: 4

174% more call options, than puts

Call options by funds: $444K | Put options by funds: $162K

125% more repeat investments, than reductions

Existing positions increased: 36 | Existing positions reduced: 16

30% more funds holding

Funds holding: 71 → 92 (+21)

9.07% more ownership

Funds ownership: 57.29% → 66.36% (+9.1%)

Holders
92
Holders Change
+21
Holders Change %
+29.58%
% of All Funds
1.99%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.02%
New
27
Increased
36
Reduced
16
Closed
4
Calls
$444​K
Puts
$162​K
Net Calls
+$282​K
Net Calls Change
-⁠$1.1​M

CALA Hedge Fund Activity: Q2 2019 in Review

92 of the 4,627 institutional investors tracked by Wall St. Rank reported a position in Calithera Biosciences (CALA) for Q2 2019, worth a combined $134M — down 11% from $150M a quarter earlier.

Buyers outnumbered sellers: 27 funds opened new CALA positions and 4 closed out — a net gain of 23 holders — while 36 added to existing stakes and 16 trimmed.

The largest buyer was BVF Inc, adding an estimated $21.2M. The largest seller was ALPS Advisors, exiting entirely with an estimated $621K sold.

  • 92 institutional investors held Calithera Biosciences (CALA) as of Q2 2019, up from 71 in Q1 2019.
  • Funds reported $134M of Calithera Biosciences stock for Q2 2019, down 11% quarter-over-quarter.
  • 27 funds opened new Calithera Biosciences positions in Q2 2019 and 4 closed out, a net change of +23 holders.
  • The largest Calithera Biosciences buyer in Q2 2019 was BVF Inc, an estimated $21.2M added.
  • The largest Calithera Biosciences seller in Q2 2019 was ALPS Advisors, an estimated $621K sold.

Based on aggregated 13F filings for Q2 2019.